Researchers Identify HIF2 as Key Driver of Coronary Damage in Kawasaki Disease, Opening New Therapeutic Avenues
Key Insights
An international team led by CNIC researchers has identified sustained hypoxia pathway activation as a fundamental mechanism driving coronary artery lesions in severe Kawasaki disease (search).
A novel mouse model with continuous HIF pathway activation faithfully reproduced coronary damage including dilation, inflammation, thrombosis, and calcification seen in patients.
Inactivation of HIF2 (search) reversed cardiovascular abnormalities and restored molecular alterations, identifying it as a key regulator of coronary inflammation and remodeling.
An international research team led by Silvia Martín-Puig at the Centro Nacional de Investigaciones Cardiovasculares Carlos III (search) (CNIC) has uncovered a fundamental mechanism driving the coronary artery damage characteristic of severe Kawasaki disease (search). The study, published in Circulation, demonstrates that sustained activation of the cellular response to oxygen deprivation—regulated by hypoxia-inducible factors (HIFs)—triggers vascular and inflammatory changes that closely mirror the coronary lesions observed in the most severe forms of this pediatric disorder.
Kawasaki disease (search) is a rare inflammatory disorder affecting blood vessels, primarily in children under five years of age. It is the leading cause of acquired cardiovascular disease in children in developed countries. In its most severe forms, generally associated with delayed diagnosis and treatment, the disease can cause coronary artery dilation, aneurysms, thrombosis, and other complications that may result in permanent cardiovascular damage and increase the risk of heart disease during adolescence and adulthood.
Despite decades of research, the mechanisms responsible for these lesions have remained poorly understood. "Understanding how coronary artery damage develops is essential for designing more effective treatments and preventing its long-term consequences," the researchers note.
A Novel Mouse Model Recapitulates Coronary Pathology
To investigate the origin of these lesions, the researchers developed a new mouse model in which the hypoxia response pathway remains continuously activated in cells involved in the formation and maintenance of the coronary arteries. The animals developed cardiovascular abnormalities closely resembling those observed in the most severe cases of Kawasaki disease (search), including coronary artery dilation, vascular inflammation, thrombosis, calcification, hemorrhage, and cardiac tissue damage.
Molecular analyses revealed changes in the expression of genes involved in inflammation, coagulation, and other processes closely associated with the progression of vascular injury. One of the key advantages of this model is its ability to faithfully recapitulate coronary artery damage—the hallmark cardiovascular manifestation of severe Kawasaki disease (search)—whereas previous experimental models primarily affected large vessels such as the aorta.
"Having a model that faithfully reproduces the alterations observed in the coronaries of patients provides us with a unique opportunity to better understand the disease and explore new therapeutic strategies," said Silvia Martín-Puig, principal investigator of the study.
HIF2 (search) Emerges as a Key Therapeutic Target
One of the study's most significant findings was the demonstration that inactivation of HIF2 (search) reverses the profound cardiovascular abnormalities developed in the experimental model and restores the molecular alterations associated with the disease. "This allowed us to identify HIF2 as a key regulator of coronary inflammation, vascular remodeling, and the thrombotic complications characteristic of the cardiovascular alterations of severe Kawasaki disease (search)," explained Martín-Puig.
Furthermore, analysis of cardiac tissue from patients with Kawasaki disease (search) revealed the presence of HIF2 (search) both within coronary lesions and in the surrounding inflammatory cells. These findings strengthen the clinical relevance of the study and identify HIF2 as a promising therapeutic target for preventing adverse cardiovascular outcomes associated with the disease.
Clinical Implications and Future Directions
Although current treatment strategies—including intravenous immunoglobulins, corticosteroids, and biological agents used in refractory cases—have demonstrated clinical efficacy in patients with Kawasaki disease (search), no therapies are currently available that specifically prevent damage to the coronary arteries. In this context, the study identifies a previously unrecognized pathway involved in the development of these lesions and opens new avenues for the development of more targeted treatments.
The study involved researchers from several institutions including the CIBER Network for Respiratory Diseases (CIBERES), the CIBER Network for Cardiovascular Diseases (CIBERCV), the August Pi i Sunyer Biomedical Research Institute (IDIBAPS), and Toho University in Tokyo. The new experimental model also represents a valuable tool for investigating the pathogenesis of the disease and evaluating interventions aimed at preventing its most serious cardiovascular complications.